{"id":"intravenous-infusion-of-aclasta","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fever"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Bone pain"}]},"_chembl":{"chemblId":"CHEMBL2109039","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Aclasta, also known as zoledronic acid, is a bisphosphonate that works by inhibiting the mevalonate pathway in osteoclasts, leading to a decrease in bone resorption.","oneSentence":"Bisphosphonate that inhibits osteoclast-mediated bone resorption","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:55:34.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoporosis in postmenopausal women"},{"name":"Treatment of bone metastases in patients with breast cancer or multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05677152","phase":"PHASE2","title":"Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder","status":"RECRUITING","sponsor":"AUVA Traumazentrum Vienna Site UKH Meidling","startDate":"2022-08-22","conditions":"Orthopedics, Traumatology","enrollment":80},{"nctId":"NCT00556374","phase":"PHASE3","title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-18","conditions":"Breast Cancer","enrollment":3420},{"nctId":"NCT01345019","phase":"PHASE3","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-17","conditions":"Cancer, Hematologic Malignancies, Multiple Myeloma","enrollment":1718},{"nctId":"NCT00740129","phase":"PHASE4","title":"Re-treatment of Participants With Paget's Disease Using Zoledronic Acid","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10-21","conditions":"Paget's Disease of the Bone","enrollment":6},{"nctId":"NCT00622505","phase":"PHASE4","title":"Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-11-07","conditions":"Multiple Myeloma","enrollment":121},{"nctId":"NCT01732770","phase":"PHASE4","title":"Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-07","conditions":"Post Menopausal Osteoporosis","enrollment":643},{"nctId":"NCT00436917","phase":"NA","title":"Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-04","conditions":"Breast Cancer, Osteoporosis","enrollment":60},{"nctId":"NCT00399802","phase":"PHASE2","title":"A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11-16","conditions":"Breast Cancer, Metastatic Bone Disease","enrollment":43},{"nctId":"NCT01907880","phase":"PHASE4","title":"The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2012-08","conditions":"Breast Cancer","enrollment":74},{"nctId":"NCT00321932","phase":"PHASE2","title":"Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2005-07","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":61},{"nctId":"NCT00172042","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Non-Small-Cell Lung Cancer","enrollment":437},{"nctId":"NCT01166178","phase":"PHASE3","title":"Zoledronic Acid in MS-patients With Osteoporosis","status":"TERMINATED","sponsor":"Novartis","startDate":"2010-10","conditions":"Osteoporosis, Multiple Sclerosis","enrollment":29},{"nctId":"NCT00171340","phase":"PHASE3","title":"Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-05","conditions":"Bone Loss, Breast Cancer","enrollment":1065},{"nctId":"NCT00375427","phase":"PHASE3","title":"Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-02","conditions":"Breast Cancer With Bone Metastasis","enrollment":430},{"nctId":"NCT00171314","phase":"PHASE3","title":"The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-03","conditions":"Breast Cancer","enrollment":527},{"nctId":"NCT00697619","phase":"PHASE2","title":"To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2005-09","conditions":"Nasopharyngeal Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Intravenous Infusion of Aclasta®","genericName":"Intravenous Infusion of Aclasta®","companyName":"AUVA Traumazentrum Vienna Site UKH Meidling","companyId":"auva-traumazentrum-vienna-site-ukh-meidling","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bisphosphonate that inhibits osteoclast-mediated bone resorption Used for Treatment of osteoporosis in postmenopausal women, Treatment of bone metastases in patients with breast cancer or multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}